Reply to "How should decision aids be developed, and which patient outcomes should be assessed?"

Affiliations

Free article

Comment

Simon P Kim et al. Cancer. 2022.

Free article

. 2022 Aug 1;128(15):2990.

doi: 10.1002/cncr.34246. Epub 2022 May 4.

No abstract available

Comment on

Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD).
Tilburt JC, Zahrieh D, Pacyna JE, Petereit DG, Kaur JS, Rapkin BD, Grubb RL 3rd, Chang GJ, Morris MJ, Kovac EZ, Babaian KN, Sloan JA, Basch EM, Peil ES, Dueck AC, Novotny PJ, Paskett ED, Buckner JC, Joyce DD, Montori VM, Frosch DL, Volk RJ, Kim SP. Tilburt JC, et al. Cancer. 2022 Mar 15;128(6):1242-1251. doi: 10.1002/cncr.34062. Epub 2021 Dec 10. Cancer. 2022. PMID: 34890060 Free PMC article. Clinical Trial.
How should decision aids be developed, and which patient outcomes should be assessed?
Diefenbach MA, Miller SM. Diefenbach MA, et al. Cancer. 2022 Aug 1;128(15):2988-2989. doi: 10.1002/cncr.34247. Epub 2022 May 4. Cancer. 2022. PMID: 35507272 Free PMC article. No abstract available.

1. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199:683-690. doi:10.1016/j.juro.2017.11.095
1. Tilburt JC, Zahrieh D, Pacyna JE, et al. Decision aids for localized prostate cancer in diverse minority men: primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD). Cancer. 2022;128:1242-1251. doi:10.1002/cncr.34062
1. Violette PD, Agoritsas T, Alexander P, et al. Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA Cancer J Clin. 2015;65:239-251. doi:10.3322/caac.21272